Pharmaceutical Benefit Plan Settlements

$52 Million pending via Pharmaceutical Benefit Plan Settlements, separate from the Generic Pharmaceuticals Pricing Antitrust Litigation.

Overview

There are typically several active lawsuits and/or class action settlements that fall into the category of “pharmaceutical benefit plan settlements.” Under these cases, it is generally alleged that businesses with self-insured health plans overpaid for drugs purchased on behalf of their employees due to artificially inflated and/or stabilized prices.

The prices were allegedly manipulated as a result of anti-competitive practices undertaken by the drug manufacturers. The number of these opportunities in any given year varies, but there can be several available at the same time.

Pending Settlement(s):

QVAR-Redihaler Settlement

Date Range: January 2015 - July 2025

Settlement Fund: $35 million

Filing Deadline: TBD

Settlement Overview: The settlement resolves claims that Teva unlawfully delayed the entry of generic QVAR, causing consumers and third-party payors to pay more than they should have for QVAR and QVAR Redihaler inhalers, which are used for the long-term treatment of asthma.

Eligible Locations: To be a member of the Settlement Class, you must have purchased, paid, and/or provided reimbursement for some or all of the purchase price of QVAR and/or QVAR Redihaler, other than for resale, in the Class States, for consumption by yourself, your family, or your members, insureds, or beneficiaries, at any time from January 1, 2015, through July 31, 2025. The class does not include Federal and state governmental entities.

Class States: Alaska, Arkansas, Arizona, California, Connecticut, Delaware, D.C., Florida, Hawaii, Illinois, Indiana, Iowa, Kansas, Maine, Massachusetts, Maryland, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Rhode Island, South Dakota, Tennessee, Texas, Utah, Virginia, Vermont, Washington, West Virginia, Wisconsin, and Wyoming.

Eligible Drugs: QVAR and QVAR Redihalers

Sartan Settlement

Date Range: January 2016-present

Settlement Fund: $17.1 million

Filing Deadline: June 2, 2026

Settlement Overview: Settlements have been reached with Hetero, Aurobindo, and Vivimed, resolving economic loss claims related to alleged contamination of certain blood pressure medications with probable human carcinogens.

Settlement Class & Eligible Drugs: Individuals and third-party payors in the U.S., its territories, and possessions who paid for the following drug formulations (other than for resale):

• Valsartan: Finished formulations containing Hetero Process III API, sold May 1 – July 31, 2018

• Irbesartan: Finished formulations manufactured using Aurobindo IC Route, purchased Jan 1, 2016 – present

• Losartan (Vivimed): Finished formulations with impacted NDCs: 23155-644-09, 23155-644-10, 23155-645-03, 23155-645-09, 23155-645-10, 23155-646-03, 23155-646-09, 23155-646-10

Exclusions: All federal and state governmental entities, except cities, towns, municipalities, or counties with self-funded prescription drug plans.

Recommended Next Steps Data is often required to complete your claim for settlements in this category. Connect us with a member of your Benefits Department so an MCAG representative can describe the information that is necessary to complete your claim for these pharmaceutical settlements. We typically only need a 5 to 10 minute call. We will quickly review the process so we can efficiently obtain necessary information from your Pharmacy Benefit Manager (i.e. CVS Caremark, Express Scripts, OptumRX) to pursue current and future pharmaceutical settlements.

Eligible contracted clients can expect to be contacted by an MCAG representative to review and assist with gathering the necessary information for these settlements.

MCAG is not the Settlement/Class Administrator, and this is not an official settlement website.

Need more information? CLICK HERE to complete our contact form and an MCAG representative will respond shortly.